Which has preferable earnings and valuation, PACS or GRAL?

PACS Group has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PACS Group $5.43B 1.34 $191.54M $1.56 29.56 GRAIL $147.17M 19.99 -$408.35M -$10.37 N/A

Is PACS or GRAL more profitable?

PACS Group has a net margin of 4.49% compared to GRAIL's net margin of -253.22%. PACS Group's return on equity of 26.47% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets PACS Group 4.49% 26.47% 4.36% GRAIL -253.22% -16.42% -14.34%

Does the media prefer PACS or GRAL?

In the previous week, GRAIL had 42 more articles in the media than PACS Group. MarketBeat recorded 49 mentions for GRAIL and 7 mentions for PACS Group. PACS Group's average media sentiment score of 1.16 beat GRAIL's score of 0.13 indicating that PACS Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PACS Group 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 5 Very Positive mention(s) 0 Positive mention(s) 43 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, GRAL or HIMS?

Hims & Hers Health has higher revenue and earnings than GRAIL. Hims & Hers Health is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $147.17M 19.99 -$408.35M -$10.37 N/A Hims & Hers Health $2.35B 2.74 $128.37M -$0.09 N/A

Is GRAL or HIMS more profitable?

Hims & Hers Health has a net margin of -0.56% compared to GRAIL's net margin of -253.22%. Hims & Hers Health's return on equity of 6.10% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets GRAIL -253.22% -16.42% -14.34% Hims & Hers Health -0.56% 6.10% 1.52%

Does the media prefer GRAL or HIMS?

In the previous week, GRAIL had 23 more articles in the media than Hims & Hers Health. MarketBeat recorded 49 mentions for GRAIL and 26 mentions for Hims & Hers Health. Hims & Hers Health's average media sentiment score of 0.22 beat GRAIL's score of 0.13 indicating that Hims & Hers Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 5 Very Positive mention(s) 0 Positive mention(s) 43 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Hims & Hers Health 6 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, BLLN or GRAL?

Billiontoone has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Billiontoone $305.11M 20.89 $7.45M $0.55 252.00 GRAIL $147.17M 19.99 -$408.35M -$10.37 N/A

Is BLLN or GRAL more profitable?

Billiontoone has a net margin of 0.00% compared to GRAIL's net margin of -253.22%. Billiontoone's return on equity of 0.00% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets Billiontoone N/A N/A N/A GRAIL -253.22% -16.42% -14.34%

Does the media favor BLLN or GRAL?

In the previous week, GRAIL had 45 more articles in the media than Billiontoone. MarketBeat recorded 49 mentions for GRAIL and 4 mentions for Billiontoone. Billiontoone's average media sentiment score of 0.41 beat GRAIL's score of 0.13 indicating that Billiontoone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Billiontoone 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GRAIL 5 Very Positive mention(s) 0 Positive mention(s) 43 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, SHC or GRAL?

Sotera Health has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sotera Health $1.16B 4.38 $77.94M $0.41 43.56 GRAIL $147.17M 19.99 -$408.35M -$10.37 N/A

Is SHC or GRAL more profitable?

Sotera Health has a net margin of 9.91% compared to GRAIL's net margin of -253.22%. Sotera Health's return on equity of 39.73% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets Sotera Health 9.91% 39.73% 7.05% GRAIL -253.22% -16.42% -14.34%

Does the media favor SHC or GRAL?

In the previous week, GRAIL had 37 more articles in the media than Sotera Health. MarketBeat recorded 49 mentions for GRAIL and 12 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.35 beat GRAIL's score of 0.13 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 5 Very Positive mention(s) 0 Positive mention(s) 43 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, GRAL or RDNT?

RadNet has higher revenue and earnings than GRAIL. RadNet is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $147.17M 19.99 -$408.35M -$10.37 N/A RadNet $2.04B 2.46 -$18.65M -$0.18 N/A

Is GRAL or RDNT more profitable?

RadNet has a net margin of -0.66% compared to GRAIL's net margin of -253.22%. RadNet's return on equity of 2.77% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets GRAIL -253.22% -16.42% -14.34% RadNet -0.66% 2.77% 0.97%

Does the media refer more to GRAL or RDNT?

In the previous week, GRAIL had 44 more articles in the media than RadNet. MarketBeat recorded 49 mentions for GRAIL and 5 mentions for RadNet. RadNet's average media sentiment score of 0.42 beat GRAIL's score of 0.13 indicating that RadNet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 5 Very Positive mention(s) 0 Positive mention(s) 43 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral RadNet 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

GRAIL (GRAL) Competitors

$68.56 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$67.78 -0.78 (-1.14%)

As of 07/31/2026 07:34 PM Eastern

Compare

GRAL vs. PACS, HIMS, BLLN, SHC, and RDNT

Should you buy GRAIL stock or one of its competitors? MarketBeat compares GRAIL with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GRAIL include PACS Group (PACS), Hims & Hers Health (HIMS), Billiontoone (BLLN), Sotera Health (SHC), and RadNet (RDNT).

How does GRAIL compare to PACS Group?

PACS Group (NYSE:PACS) and GRAIL (NASDAQ:GRAL) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, GRAIL had 42 more articles in the media than PACS Group. MarketBeat recorded 49 mentions for GRAIL and 7 mentions for PACS Group. PACS Group's average media sentiment score of 1.16 beat GRAIL's score of 0.13 indicating that PACS Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PACS Group	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	5 Very Positive mention(s)	0 Positive mention(s)	43 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

PACS Group has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market. Comparatively, GRAIL has a beta of 3.24, indicating that its stock price is 224% more volatile than the broader market.

PACS Group presently has a consensus target price of $50.60, suggesting a potential upside of 9.72%. GRAIL has a consensus target price of $67.78, suggesting a potential downside of 1.14%. Given PACS Group's stronger consensus rating and higher probable upside, equities analysts plainly believe PACS Group is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

PACS Group has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$5.43B	1.34	$191.54M	$1.56	29.56
GRAIL	$147.17M	19.99	-$408.35M	-$10.37	N/A

PACS Group has a net margin of 4.49% compared to GRAIL's net margin of -253.22%. PACS Group's return on equity of 26.47% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PACS Group	4.49%	26.47%	4.36%
GRAIL	-253.22%	-16.42%	-14.34%

Summary

PACS Group beats GRAIL on 11 of the 14 factors compared between the two stocks.

How does GRAIL compare to Hims & Hers Health?

GRAIL (NASDAQ:GRAL) and Hims & Hers Health (NYSE:HIMS) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

GRAIL has a beta of 3.24, indicating that its share price is 224% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.4, indicating that its share price is 140% more volatile than the broader market.

Hims & Hers Health has a net margin of -0.56% compared to GRAIL's net margin of -253.22%. Hims & Hers Health's return on equity of 6.10% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-253.22%	-16.42%	-14.34%
Hims & Hers Health	-0.56%	6.10%	1.52%

In the previous week, GRAIL had 23 more articles in the media than Hims & Hers Health. MarketBeat recorded 49 mentions for GRAIL and 26 mentions for Hims & Hers Health. Hims & Hers Health's average media sentiment score of 0.22 beat GRAIL's score of 0.13 indicating that Hims & Hers Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	5 Very Positive mention(s)	0 Positive mention(s)	43 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hims & Hers Health	6 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	2 Very Negative mention(s)	Neutral

Hims & Hers Health has higher revenue and earnings than GRAIL. Hims & Hers Health is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	19.99	-$408.35M	-$10.37	N/A
Hims & Hers Health	$2.35B	2.74	$128.37M	-$0.09	N/A

63.5% of Hims & Hers Health shares are owned by institutional investors. 1.8% of GRAIL shares are owned by insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GRAIL presently has a consensus price target of $67.78, indicating a potential downside of 1.14%. Hims & Hers Health has a consensus price target of $31.43, indicating a potential upside of 13.12%. Given Hims & Hers Health's higher possible upside, analysts plainly believe Hims & Hers Health is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19

Summary

Hims & Hers Health beats GRAIL on 10 of the 15 factors compared between the two stocks.

How does GRAIL compare to Billiontoone?

Billiontoone (NASDAQ:BLLN) and GRAIL (NASDAQ:GRAL) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Billiontoone presently has a consensus price target of $126.00, indicating a potential downside of 9.09%. GRAIL has a consensus price target of $67.78, indicating a potential downside of 1.14%. Given GRAIL's higher possible upside, analysts clearly believe GRAIL is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

In the previous week, GRAIL had 45 more articles in the media than Billiontoone. MarketBeat recorded 49 mentions for GRAIL and 4 mentions for Billiontoone. Billiontoone's average media sentiment score of 0.41 beat GRAIL's score of 0.13 indicating that Billiontoone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Billiontoone	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GRAIL	5 Very Positive mention(s)	0 Positive mention(s)	43 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Billiontoone has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Billiontoone	$305.11M	20.89	$7.45M	$0.55	252.00
GRAIL	$147.17M	19.99	-$408.35M	-$10.37	N/A

Billiontoone has a net margin of 0.00% compared to GRAIL's net margin of -253.22%. Billiontoone's return on equity of 0.00% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Billiontoone	N/A	N/A	N/A
GRAIL	-253.22%	-16.42%	-14.34%

Summary

Billiontoone beats GRAIL on 11 of the 13 factors compared between the two stocks.

How does GRAIL compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and GRAIL (NASDAQ:GRAL) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

In the previous week, GRAIL had 37 more articles in the media than Sotera Health. MarketBeat recorded 49 mentions for GRAIL and 12 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.35 beat GRAIL's score of 0.13 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	9 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	5 Very Positive mention(s)	0 Positive mention(s)	43 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sotera Health has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, GRAIL has a beta of 3.24, indicating that its stock price is 224% more volatile than the broader market.

Sotera Health currently has a consensus target price of $20.25, indicating a potential upside of 13.38%. GRAIL has a consensus target price of $67.78, indicating a potential downside of 1.14%. Given Sotera Health's stronger consensus rating and higher probable upside, analysts plainly believe Sotera Health is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

91.0% of Sotera Health shares are owned by institutional investors. 15.4% of Sotera Health shares are owned by company insiders. Comparatively, 1.8% of GRAIL shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Sotera Health has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	4.38	$77.94M	$0.41	43.56
GRAIL	$147.17M	19.99	-$408.35M	-$10.37	N/A

Sotera Health has a net margin of 9.91% compared to GRAIL's net margin of -253.22%. Sotera Health's return on equity of 39.73% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	9.91%	39.73%	7.05%
GRAIL	-253.22%	-16.42%	-14.34%

Summary

Sotera Health beats GRAIL on 13 of the 16 factors compared between the two stocks.

How does GRAIL compare to RadNet?

GRAIL (NASDAQ:GRAL) and RadNet (NASDAQ:RDNT) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

In the previous week, GRAIL had 44 more articles in the media than RadNet. MarketBeat recorded 49 mentions for GRAIL and 5 mentions for RadNet. RadNet's average media sentiment score of 0.42 beat GRAIL's score of 0.13 indicating that RadNet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	5 Very Positive mention(s)	0 Positive mention(s)	43 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
RadNet	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

77.9% of RadNet shares are owned by institutional investors. 1.8% of GRAIL shares are owned by company insiders. Comparatively, 5.1% of RadNet shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GRAIL has a beta of 3.24, meaning that its stock price is 224% more volatile than the broader market. Comparatively, RadNet has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

GRAIL presently has a consensus price target of $67.78, suggesting a potential downside of 1.14%. RadNet has a consensus price target of $87.43, suggesting a potential upside of 37.08%. Given RadNet's stronger consensus rating and higher probable upside, analysts plainly believe RadNet is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
RadNet	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.80

RadNet has higher revenue and earnings than GRAIL. RadNet is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	19.99	-$408.35M	-$10.37	N/A
RadNet	$2.04B	2.46	-$18.65M	-$0.18	N/A

RadNet has a net margin of -0.66% compared to GRAIL's net margin of -253.22%. RadNet's return on equity of 2.77% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-253.22%	-16.42%	-14.34%
RadNet	-0.66%	2.77%	0.97%

Summary

RadNet beats GRAIL on 13 of the 17 factors compared between the two stocks.

Get GRAIL News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRAL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRAL vs. The Competition

Export

Metric	GRAIL	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.94B	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-6.61	7.38	282.27	24.66
Price / Sales	19.99	1,250.98	581.52	86.64
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	1.04	16.78	10.93	6.07
Net Income	-$408.35M	-$12.56M	$3.49B	$347.99M
7 Day Performance	2.68%	-1.82%	-0.64%	-0.42%
1 Month Performance	-0.80%	-8.45%	-3.78%	-4.80%
1 Year Performance	109.09%	48.33%	61.99%	18.61%

GRAIL Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRAL GRAIL	1.064 of 5 stars	$68.56 flat	$67.78 -1.1%	+109.1%	$2.94B	$147.17M	N/A	1,360	Trending News Upcoming Earnings Gap Up
PACS PACS Group	3.5244 of 5 stars	$46.95 +0.2%	$50.60 +7.8%	+334.3%	$7.42B	$5.43B	30.09	47,455	Upcoming Earnings
HIMS Hims & Hers Health	3.1428 of 5 stars	$30.23 +7.6%	$31.43 +4.0%	-55.6%	$7.00B	$2.37B	N/A	2,442	Trending News Upcoming Earnings Gap Down
BLLN Billiontoone	2.6137 of 5 stars	$127.98 +1.5%	$126.00 -1.5%	N/A	$5.80B	$305.11M	232.69	620
SHC Sotera Health	3.8878 of 5 stars	$17.24 -0.6%	$20.25 +17.5%	+60.2%	$4.92B	$1.19B	42.05	3,000	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRAL) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GRAIL (GRAL) Competitors